Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pharvaris N.V. (NQ: PHVS )

24.15 -0.72 (-2.90%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 46,135
Open 24.61
Bid (Size) 9.770 (2)
Ask (Size) 39.05 (2)
Prev. Close 24.87
Today's Range 23.89 - 24.68
52wk Range 15.00 - 33.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Pharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific Meeting
Data from randomized clinical studies and long-term extension studies support deucrictibant’s potential best-in-class profile, detailing its injectable-like efficacy, placebo-like tolerability, and... 
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings
From Pharvaris N.V.
Via GlobeNewswire

Performance

YTD
-6.65%
-6.65%
1 Month
+34.99%
+34.99%
3 Month
+40.24%
+40.24%
6 Month
+6.48%
+6.48%
1 Year
+30.68%
+30.68%

More News

Read More
Pharvaris to Host Virtual Investor Event on October 23, 2024
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Provides Business Update and Expands Development Program for Deucrictibant
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Presents Data at the Bradykinin Symposium 2024
From Pharvaris N.V.
Via GlobeNewswire
Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium
From Pharvaris N.V.
Via GlobeNewswire
PHVS Stock Earnings: Pharvaris Beats EPS for Q2 2024
Via InvestorPlace
Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business Update
From Pharvaris N.V.
Via GlobeNewswire
Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense
Via Investor's Business Daily
Pharvaris Announces Annual Meeting of Shareholders
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses
From Pharvaris N.V.
Via GlobeNewswire
PHVS Stock Earnings: Pharvaris Misses EPS for Q1 2024
Via InvestorPlace
Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update
From Pharvaris N.V.
Via GlobeNewswire
PHVS Stock Earnings: Pharvaris Misses EPS for Q4 2023
Via InvestorPlace
Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris to Participate in the Leerink Global Biopharma Conference 2024
From Pharvaris N.V.
Via GlobeNewswire
Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Announces Extraordinary Meeting of Shareholders
From Pharvaris N.V.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.